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Background: Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting
pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative
efficacies of PEGV + SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of
PEGV vs. PEGV + SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates,
doses required to achieve control).
Methods: A retrospective analysis of data collected in 2005–2010 in five hospital-based endocrinology centers in
Rome was performed. Sixty-two adult acromegaly patients treated ≥6 months with PEGV (Group 1, n = 35) or PEGV +
SSA (Group 2, n = 27) after unsuccessful maximal-dose SSA monotherapy (≥12 months) were enroled. Groups were
compared in terms of clinical/biochemical characteristics at diagnosis and before PEGV or PEGV + SSA was started
(baseline) and end-of-follow-up outcomes (IGF-I levels, adverse event rates, final PEGV doses).
Results: Group 2 showed higher IGF-I and GH levels and sleep apnea rates, higher rates residual tumor tissue at
baseline, more substantial responses to SSA monotherapy and worse outcomes (IGF-I normalization rates, final IGF-I
levels). Tumor growth and hepatotoxicity events were rare in both groups. Final daily PEGV doses were similar and
significantly increased with treatment duration in both groups.
Conclusions: PEGV and PEGV + SSA are safe, effective solutions for managing SSA-refractory acromegaly. PEGV + SSA
tends to be used for more aggressive disease associated with detectable tumor tissue. With both regimens, ongoing
monitoring of responses is important since PEGV doses needed to maintain IGF-I control are likely to increase over
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Elevated GH and IGF-I levels are major causes of mor-
bidity and mortality in patients with acromegaly [1,2].
The mainstay of treatment involves surgical resection of
the somatotrophic adenoma causing the disease. In experi-
enced hands, it is associated with cure rates of 50-70%, de-
pending on the size, morphology, and location of the
tumor. Management of inoperable, residual, or relapsing
disease is based on radiation and medical therapies. Long-
acting somatostatin analogs (SSA), the drugs generally
used for this purpose, restore “safe” levels of GH and IGF-
I in 50-75% of acromegalic patients and produce some de-
gree of tumor shrinkage in 50–80% [3-5].
Pegvisomant (PEGV), a pegylated recombinant human
GH analog that acts as a GH-receptor antagonist, was
approved by the European Medicines Agency in 2002
for treatment of acromegaly in patients with inadequate
responses (or contraindications) to surgery and/or radi-
ation therapy and to SSA monotherapy [6]. The indica-
tions approved in 2003 by the U.S. Food and Drug
Administration were somewhat broader and included
patients who could not be controlled (or tolerate) sur-
gery and/or radiation and/or other medical therapies [7].
Numerous studies have documented PEGV’s efficacy in
patients with persistent active acromegaly, with IGF-I
normalization rates ranging from 63% to 97% [8-11].
Recent guidelines suggest that combination therapy
with PEGV and an SSA (PEGV + SSA) may also be use-
ful for patients whose acromegaly is poorly controlled by
conventional approaches [5]. It has also been proposed
as a more cost-effective alternative for patients who re-
quire high-dose PEG monotherapy [12-14]. A recent
international survey [15] revealed that this approach is
used in 94% of centers surveyed in the United States and
76% of those in Europe, and over 90% of the centers
reported using combination therapy only after SSA
monotherapy had failed. No information, however, is
available on the criteria used by physicians in deciding to
prescribe PEGV + SSA rather than PEGV monotherapy.
A small, short-term study by Trainer et al. found that
the two approaches were equally effective in normalizing
IGF-I levels in patients who are not controlled on SSA
monotherapy [16]. Other investigators have suggested
that PEGV + SSA might be useful to control tumor
growth and improve glucose tolerance [13,14,17], but
these hypotheses were not confirmed in subsequent
studies [18-20]. Thus far, there have been no long-term
prospective or retrospective studies directly comparing
the outcomes of the two treatment regimens.
The aims of the present study were to characterize the
use in five Italian hospitals of PEGV vs. PEGV + SSA
regimens for the treatment of SSA-resistant acromegaly
in terms of patient selection, long-term outcomes, ad-
verse event rates, and doses required to achieve control.Methods
Subjects, treatment, and follow-up protocols
We conducted a retrospective analysis of data collected
between 1 March 2005 and 31 December 2010 in five
hospital-based endocrinology centers in Rome, Italy. The
protocol was approved by the Research Ethics Commit-
tees of each center, and all patients provided written, in-
formed consent to review of their charts and publication
of the study findings. Data were recorded on electronic
forms by physicians involved in the patients’ care and
sent to the Coordinating Center for analysis.
The inclusion criteria were: [1] active acromegaly [i.e.
GH concentrations above 1 ng/ml after OGTT together
with fasting plasma IGF-I concentrations above the nor-
mal ranges for age and sex; [2] treatment with long-acting
SSA for at least 12 months at maximum tolerated dose
[Octreotide LAR 30 mg/4 weeks or Lanreotide Autogel
(ATG) 120 mg/4 weeks]; [3] resistance to SSA, defined by
high serum IGF-I concentrations despite maximal dose of
SSAs for at least 1 years, according to Colao and co-
workers [21]; [4] treatment with PEGV alone or in
addition to SSAs for at least 6 months; [5] available infor-
mations, before PEGV start, about the following evaluated
and recorded comorbidities: hypopituitarism, hyperten-
sion, diabetes, cardiomyopathy, sleep apnea, vertebral frac-
ture, goiter and colon cancer.
Pegvisomant (Somavert, Pfizer Italia S.r.l., Rome, Italy)
mono- and combination-therapy regimens were pre-
scribed by the attending physicians. The drug was
administered subcutaneously, once or twice daily (de-
pending on dose); loading doses were not used and
starting dose was 10 mg/day s.c. in all patients. Dosage
adjustments (± 5 mg/day ) were based on IGF-I re-
sponses after one month and every two months for the
first year of treatment.
After the first year, patients were re-evaluated at least
every six months and each visit included assays of serum
IGF-I levels and serum transaminase levels (ALT and
AST); pituitary imaging studies (magnetic resonance im-
aging [MRI]) were performed every year.
During the 6-year study period, all participating cen-
ters used the same assays (Immulite 2000, DPC, Los
Angeles, CA) to measure GH (before PEGV start) and
IGF-I concentrations (Interassay coefficients of variation:
5.5%–6.2% for GH assays, 6.4%–11.5% for IGF-1: detec-
tion limits: 0.01 μg/L and 0.2 μg/L, respectively). GH
levels are measured in μg/L of IS 98/574 (1 mg corre-
sponding to three international units somatropin) and
are specified to be means of day curves (4 sampling time
points collected over 2 hours).
Data analysis and statistical methods
Enrolled patients were retrospectively divided into two
groups: those who received PEGV monotherapy (Group
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plore the rationale underlying physicians’ decision to
prescribe the combination regimen, we compared the
group characteristics at the time of diagnosis and at
baseline (i.e., at the end of unsuccessful SSA monother-
apy, right before PEGV therapy was started) (Table 1).
IGF-I levels were analyzed as absolute concentrations
and standard deviation scores (SDS) relative to normal
age-adjusted adult values (normal range from −2 to + 2
SDS). The formula used for the latter was: SDS = (In-
value – mean of normal age-adjusted values)/standard
deviation of mean of normal age-adjusted values) [22].
Baseline values had been measured with Immulite as-
says, but various assays had been used to measure values
at the time of diagnosis. Therefore, changes in serum
IGF-I levels from diagnosis to baseline (IGF-I Δ) were
calculated using the IGF-I SDSs recorded at the two
time points. Outcomes of PEGV therapy were assessed
in terms of absolute IGF-I levels and SDS values
recorded during follow-up. Safety was evaluated in terms
of the percentage of patients who experienced significant
CT- or MRI-documented adenoma enlargement (i.e.,
volume increase over baseline of > 25% or at least 0.5 cc)
[20]; significant elevations in serum ALT and/or AST (at
least 1 test with values >3 times the upper limit of nor-
mal); and injection site events.
Intragroup differences involving continuous variables
were analyzed with the Wilcoxon rank sum test; the
Mann–Whitney U test when data from different groups
were being compared. For discontinuous variables, the
chi-squared test was used. Multivariate logistic regres-
sion analysis was used to identify factors related to the
decision to prescribe PEGV + SSA vs. PEGV monother-
apy. Standard and stepwise multiple linear regression
analyses were used to identify variables that best pre-
dicted the end-of-follow-up PEGV dose. P values <0.05
were regarded as significant.
Results
The study population included 62 patients with acro-
megaly caused by GH-secreting adenomas (Table 1).
The vast majority had presented with macroadenomas.
Almost all had already undergone surgery, but at base-
line 2/3 had detectable residual adenoma. Three patients
were treated with SSA as primary therapy: in two cases
because the neurosurgery was contraindicated due to se-
vere cardiomyopathy and respiratory comorbidities and
in the last case the patient refused surgery. All had re-
ceived ≥ 2 years of SSA monotherapy. All patients were
on SSA treatment [octreotide LAR n = 23 (37%),
lanreotide ATG n = 39 (63%)] before PEGV replaced or
was added to SSA.
Laboratory data obtained right before this treatment
was discontinued (i.e., baseline) revealed the persistenceof markedly elevated GH (median nadir 18 μg/L) and
IGF-I levels (median 621 μg/L). The mean IGF-I Δ was
132 μg/L (range −411 to 872).
Thirty-five of the patients had been treated with PEGV
alone (Group 1) and 27 were receiving PEGV + SSA
(Group 2), continuing the previous SSA treatment. As
shown in Table 1, median GH and IGF-I levels docu-
mented at the time of diagnosis were significantly higher
in Group 2 (p < 0.05 vs. Group 1), but the frequencies of
hypopituitarism in the two groups were similar. Rates of
individual comorbidities were also similar, with the
exception of sleep apnea, which was more common
in Group 2. At baseline, there were no significant
intergroup differences in disease duration, BMIs, or
treatment histories. Before PEGV, no differences in
octreotide LAR and lanreotide ATG treated patients
were found between the two groups [Group 1: octreotide
LAR = 14 (40%), Lanreotide ATG = 21 (69%) patients;
Group 2: octreotide LAR = 9 (33%), Lanreotide ATG =
18 (67%)]. However, Group 2 had significantly higher re-
sidual tumor rates and (as at diagnosis) GH levels that
were nnearly twice as high as those of Group 1. Baseline
IGF-I levels in both groups still clearly exceeded normal
ranges. However, the IGF-I Δ values (SDS) in Group 2
were 3–4 times higher than that of Group 1. As a result,
when SSA monotherapy was discontinued (i.e., baseline),
the IGF-I elevations in the two groups were not signifi-
cantly different (Table 1). Multivariate logistic regression
analyses revealed that the decision to prescribe PEGV +
SSA vs. PEGV was significantly correlated with the pres-
ence of detectable tumor at baseline (p = 0.002) and with
the IGF-I response to previous therapy reflected in the Δ
IGF-I (p = 0.001) (Table 2).
Table 3 shows the treatment outcomes and adverse ef-
fects (AEs) reported during follow-up. The duration of
PEGV therapy was significantly longer in Group 1 (p <
0.05), but the daily doses being administered in the two
groups at the end of follow-up were similar. Both regi-
mens were generally well tolerated (Table 3). None of
the patients on monotherapy displayed significant tumor
growth, and in one case MRI documented progressive
shrinkage of the adenoma, which was no longer detect-
able after 6 years of treatment. In Group 2, significant
growth (> 25%) of residual adenoma tissue was observed
in only one case. The patient had always had very ag-
gressive disease that was difficult/impossible to control,
and when the tumor enlargement was noted, he was
receiving PEGV 40 mg/day plus lanreotide ATG
120 mg every 4 weeks. Eight (12.9%) patients (five in
Group 1, three in Group 2) experienced significant
hypertransaminasemia. Six of these had diabetes, and
five had elevated IGF-I levels at end of follow-up. Daily
PEGV doses at the time of the hypertransaminasemia
varied: three patients were receiving 30 mg, four were
Table 1 Characteristics of groups 1 and 2 at acromegaly diagnosis and at baseline
All patients Group 1 PEGV Group 2 PEGV + SSA
A Patients – n (%) 62 a 35 (56.4) 27 (43.6)
T Males 21 (33.9) 11 (31) 10 (37)
D Age at diagnosis (y) - median (range) 33 (18–72) 39 (21–72) 31 (18–70)
I Patients with macroadenomas – n (%) 50 (83%) 28 (80) 22 (81.5)
A Comorbidities - n (%)
G Hypertension 25 (40.3) 15 (42.8) 10 (37)
N Diabetes 22 (35.5) 15 (42.8) 7 (25.9)
O Cardiomyopathy 23 (37.1) 12 (34.2) 11 (40.7)
S Sleep apnea 24 (38.7) 6 (17.1) 18 (66.6)*
I Vertebral fractures 16 (25.8) 12 (34.2) 4 (14.8)
S Goiter 23 (27.1) 12 (34.2) 11 (40.7)
Colon cancer 3 (4.8) 1 (2.8) 2 (7.4)
Hypopituitarism – n (%) 27 (43.5) 13 (37.1) 14 (51.8)
ACTH deficiency 4 (6.5) 2 (5.7) 2 (7.4)
LH/FSH deficiency 25 (40.3) 13 (37.1) 12 (44.4)
TSH deficiency 7 (11.3) 5 (14.2) 2 (7.4)
Vasopressin deficiency 0 (0) 0 (0) 0 (0)
Hyperprolactinemia – n (%) 12 (19.3) 6 (17.1) 6 (22.2)
GH nadir - μg/L b
Median (range) 10.25 (2.2-100) 9.4 (2.2-63.1) 17.1 (3.3-100)*
Mean (±SD) 22.2 (±23) 16.9 (±17.3) 29 (±27.6)*
IGF-I levels
μg/L, Median (range) 715 (315–1587) 670 (315–1210) 899 (425–1587)*
SDS (range) 9.9 (2.9-22.2) 8.8 (2.9-22.2) 10.9 (3.6-21.7)*
ng/ml, Mean (±SD) 804 (±246) 723 (±216) 906 (±254)
A BMI (kg/m2) – median (range) 28.7 (19.1-42) 27 (20–42) 30 (19.1-37.8)
T Estimated disease duration (y) – median (range) 5 (2–20) 5 (2–20) 5 (2–20)
B Previous treatments – n (%)
A Surgery – n (%) 59 (95.2) 33 (94.2) 26 (96.3)
S Residual adenoma 39 (62.9) 17 (51.5) 22 (84.6)*
E Somatostatin analogs - n (%) 62 (100) 35 (100) 27 (100)
L Duration of treatment (y) – median (range) 4 (2–17) 4 (2–16) 4 (2–17)
I Radiotherapy - n (%) 16 (25.8) 7 (20) 9 (33)
N Dopamine agonists - n (%) 13 (20.9) 7 (20) 6 (22)
Ec GH levels - μg/L d
Median (range) 11 (0.8-77) 8.4 (0.8-77) 18 (3.8-74.0)*
Mean (±SD) 21.4 (±21) 17.2 (±19.7) 30.9 (±22.5)*
IGF-I levels
μg/L , Median (range) 621.5 (431–1621) 632 (431–1621) 592 (455–929)#
SDS (range) 6.9 (2.7-19.5) 6.9 (2.7-19.1) 5.9 (3.4-16.5)#
μg/L , Mean (±SD) 673(±224) 736 (±258) 661 (±162)#
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Table 1 Characteristics of groups 1 and 2 at acromegaly diagnosis and at baseline (Continued)
Δ IGF-I e
μg/L , Median (range) 132 (−411-872) 57 (−411-692) 205 (−115-872)*
SDS (range) 2 (−5.8-13.4) 0.9 (−5.8-11.2) 3.1 (−1.7-13.4)*
μg/L , Mean (±SD) 131 (±266) 38 (±250) 251 (±241)*
The results are shown as median (range) or number (percent), unless otherwise specified. Abbreviations: BMI body mass index, PEGV pegvisomant, SSA
somatostatin analogs, SDS standard deviation score.
Systeme Internationale conversion factors: GH (μg/L), X 3.0 =mUI/L; IGF-I (μg/L), X 0.131 = nmol/L.
a Nineteen were analyzed in the Acrostudy Italy;
b GH nadir = value observed after oral glucose tolerance test (OGTT);
c Baseline: End of SSA monotherapy, immediately before PEGV was started.
d Expressed as averages of GH day curve (4 points over 2 hours).
e Level observed at diagnosis minus level observed at baseline.
* p < 0.05 vs. Group 1 (Mann–Whitney U test); # p < 0.05 vs. diagnosis (Wilcoxon rank sum test).
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resolved spontaneously without treatment interruption
or dose reductions. Two AEs at the injection site were
observed (one in each group).
It is important to note that in most cases the final
doses shown in Table 3 are also the maximum doses
prescribed for the patients. In 9 cases (five in Group 1,
four in Group 2), however, PEGV doses that initially
normalized IGF-I levels had to be reduced later because
values dropped below the normal range. In Group 1, the
dose reduction was followed by IGF-I re-normalization
in 4 cases and increases to abnormally high levels in the
fifth. In contrast, re-normalization was observed in only
1 of the 4 patients in Group 2 whose doses had been de-
creased: in the other 3 cases, the dose reduction resulted
in end-of-follow-up levels that exceeded normal limits.
IGF-I normalization was thus achieved at least once dur-
ing follow-up in 47 (75.8%) patients, but only 43 (69.4%)
of these were still controlled at the end of follow-up. As
shown in Table 3, the latter outcome was significantly
more common in Group 1 (p < 0.05).
End-of-follow-up IGF-I values (Table 3) were also sig-
nificantly lower in Group 1, although both groups expe-
rienced significant reductions relative to baseline levels
(see Table 1). As shown in Table 3, analysis of the PEGV
doses in subgroups with normal and elevated IGF-I
levels at the end of follow-up revealed no significantTable 2 Logistic regression analysis: variables
determining the decision to prescribe PEGV with or
without SSA therapy (dependent variable)
COVARIATES OR (95% CI) P
GH at baseline (μg/L) 1.015 (0.983-1.043) 1.047
IGF-I SDS at baseline 1.003 (0.999-1.007) 0.097
Δ IGF I a SDS 1.446 (1.153-1.814) 0.001
Detectable adenoma at baseline b 13.757 (2.547-74.307) 0.002
Abbreviations: CI confidence intervals, OR odds ratios, PEGV pegvisomant, SSA
somatostatin analogs.
a SDS observed at diagnosis minus SDS observed at baseline.
b Includes patients who had not had surgery and those who had undergone
surgery but presented residual tumor at baseline.differences between the normalized subsets of Groups 1
and 2. However, in Group 2 patients whose end-of-
follow-up IGF-I levels were still elevated, the final PEGV
doses were significantly higher than those used in non-
normalized patients in Group 1. Indeed, this subset was
the only one in which the median dose increased signifi-
cantly as compared to that prescribed at baseline.
To identify factors influencing the daily PEGV dose
being used at the end of our follow-up, we performed
multiple linear regression analysis using standard and
stepwise methods. The covariates included in the model
were treatment regimen (PEGV vs. PEGV + SSAs), de-
tectable adenoma at baseline, baseline GH level, Δ IGF-I
SDS, sex, previous radiotherapy, and duration of PEGV
therapy. Treatment duration was the only factor signifi-
cantly correlated with the final PEGV dose, regardless of
whether it was expressed in milligrams per day (standard
regression: B = 0.451±0.059; p = 0.017; stepwise regres-
sion: B = 0.117±0.052; p = 0.026) (Figure 1) or in milli-
grams per day per BMI (standard regression: B = 0.004±
0.002; p = 0.031; stepwise regression: B = 0.004±0.022;
p = 0.025). Longer treatment was associated with signifi-
cantly higher daily doses when Groups 1 and 2 were an-
alyzed together (Figure 1A) or separately (Figure 1B-C).
The correlation was also significant when we analyzed
all patients from Groups 1 and 2 whose final IGF-I levels
were normal (Figure 2A), but not when analysis was lim-
ited to patients whose final IGF-I levels exceeded normal
ranges (Figure 2B).
Discussion
This retrospective, observational study was conducted in
5 Italian hospitals to characterize the use of PEGV vs.
PEGV + SSA regimens to manage SSA-resistant acro-
megaly. We found that combination therapy was more
likely to be prescribed for patients with clinical/bio-
chemical/imaging evidence of relatively severe/aggressive
disease along with a more substantial (albeit incomplete)
IGF-I response to SSA monotherapy. Both regimens
were well tolerated, and at the end of follow-up, there
Table 3 End-of-follow-up findings in Groups 1 and 2
Group 1 PEGV Group 2 PEGV + SSA
Patients – n (%) 35 (56.4) 27 (43.6)
Duration (mo.) of PEGV therapy – median (range) 51 (15–72) 30 (6–72)*
Final weekly PEGV dose (mg) – median (range) 105 (70–210) 140 (70–280)
Final daily PEGV dose (mg)
10 mg – n (%) 10 (28.6) 11(40.7)
15 mg – n (%) 11 (31.4) 2 (7.4)
20 mg – n (%) 9 (25.7) 8 (29.6)
25 mg – n (%) 1 (2.8) 1 (3.7)
30 mg – n (%) 4 (11.4) 4 (14.8)
40 mg – n (%) 0 (0) 1 (3.7)
Group mean (±SD) 16.8 (±6.3) 17.9 (±8.4)
Group median (range) 15 (10–30) 20 (10–40)
Subgroup with IGF-I normalization at end of follow-up 15 (10–30) 10 (10–30)
Subgroup with abnormal IGF-I levels at end of follow-up 15 (10–20) 20 (10–40)*#
Pts. requiring dose reduction during follow-up a – n (%) 5 (14.3) 4 (14.8)
Pts. with IGF-I normalization at any time during follow-up b– n (%) 29 (82.8) 18 (66.7)
Pts. with IGF-I normalization at end of follow-up – n (%) 28 (80) 15 (55.5)*
Final IGF-I levels
μg/L,Median (range) 212 (110–1216)# 291 (150–1015)*#
SDS (range) 1.0 (−0.5–14.1)# 1.9 (−0.4–9.8)*#
μg/L,Mean (±SD) 269 (± 203) 372 (± 216)*#
Significant growth of (residual) adenoma - n (%) 0 (0) 1 (3.7)
Increase of liver enzymes - n (%) 5 (14.3) 3 (11.1)
Injections site events - n (%) 1 (2.9) 1 (3.7)
a For these patients alone, final doses do not necessarily correspond to maximal doses.
b Includes pts. whose IGF-I levels were not normalized at the end of follow-up.
* p < 0.05 vs. Group 1; # = p < 0.05 vs. baseline IGF-I levels.
The results are shown as median (range) or number (percent), unless otherwise specified. Systeme Internationale conversion factors: IGF-I (μg/L)
X 0.131 = nmol/liter.
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doses in the two groups. However, outcomes (IGF-I
normalization rates and final IGF-I SDS) were signifi-
cantly worse in the patients receiving PEGV + SSA. The
only variable significantly related to the final PEGV
doses in both groups was treatment duration.
Given the size and nature of our sample, it is difficult to
tell whether and to what extent our observations on pre-
scribing practices are indicative of practices in other hos-
pitals in Italy or other countries. The tendency to
prescribe PEGV+ SSA for acromegaly patients with more
severe disease has not emerged from previous studies
[8,9,12,13,16,23,24]. The only difference noted by Filopanti
et al. in the Italian cohort they investigated was that pa-
tients on PEGV + SSA were more likely to have had
macroadenomas at the time of diagnosis [24]. This was
not observed in our population, although our Group 2 pa-
tients did have higher postoperative rates of residual
tumor tissue. The increased disease severity in Group 2was manifested by GH and IGF-I levels at diagnosis that
were significantly higher than those in the group treated
with PEGV alone. Our two treatment groups—like those
analyzed by Reid et al. [25]—also had similar comorbidity
rates when the disease was diagnosed. The exception was
sleep apnea, which was roughly three times more com-
mon in Group 2. This disorder is being reported with in-
creasing frequency in acromegaly patients [25], and its
correlation with disease activity (IGF-I levels) has been
demonstrated [26]. According to Roemmler et al. [26], our
data confirm that sleep apnea is a frequent problem
among patients whose disease is poorly controlled, espe-
cially those who present with more severe disease activity.
Clear-cut guidelines on the selection of patients for
PEGV + SSA therapy (instead of PEGV alone) are lack-
ing, although Melmed et al. note that combination ther-
apy might be more cost-effective in patients who would
otherwise require high-dose PEGV monotherapy [5]. In
our population, the decision to use PEGV + SSA was
Figure 1 Relationship between duration of PEGV therapy and
final daily dose according to treatment regimen. Correlation
between duration of PEGV therapy (months) and final daily PEGV
dose (mg/day) in the total study population (A, upper panel, ●),
Group 1 (B, middle panel, ■), and Group 2 (C, lower panel▲).
Regression coefficients (r) and p values are shown.
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tion observed after ≥ 12 months of SSA monotherapy,
which was approximately three times higher in Group 2
than in Group 1. This may reflect prescribers’ belief that,
as suggested by Colao et al. [21], the efficacy of SSA
therapy (in terms of biochemical control and limitation
of tumor growth) may emerge only after several years of
therapy, particularly when at least some positive effects
have been observed with SSA monotherapy. The most
important factor in prescribing decisions, however, was
the presence or post-operative persistence of MRI-
documented tumor tissue. Recent data indicate that the
fear of increased tumor growth during PEGV monother-
apy is unfounded [19,27], and our experience confirms
this conclusion. Significant increases in tumor volume
were extremely rare during follow-up (median duration
37 months) and showed no relation to the treatment
regimen (PEGV vs. PEGV + SSA). Transaminase eleva-
tion rates were also low, which is consistent with previ-
ous reports [11,27], and, as noted by other investigators
[17], these episodes occurred mainly in diabetics.
The IGF-I normalization rates observed in the two groups
were in line with those recently reported by Van der Lely
et al. [11]. They differ, however, from those reported in other
studies, involving patients who had less severe disease at
baseline than ours (especially those on combination therapy)
and were followed for shorter periods of time. In these stud-
ies IGF-I normalization rates achieved with PEGV and
PEGV+ SSA often exceeded 90%, especially in the early
studies with follow-ups of <52 weeks [8,9,12,13] but also in
the long-term study conducted by Neggers et al. [14]. Rates
more similar to our own were reported in 2011 by
Van der Lely et al. [23] in patients with “partial” SSA-
resistance treated PEGV+ SSA: 78.9% achieved IGF-I
normalization at least once, and 58% were still controlled at
the end of follow-up. The final PEGV doses in that study
were far lower than those recorded in our population,
reflecting once again the severity of the disease in our pa-
tients. Inadequate dosing by the prescribing physician and/
or poor patient compliance may also have contributed to
the lower-than-expected normalization rates we observed.
As noted by other authors [11], dose increases to > 20 mg/
day sometimes meet with poor compliance because they re-
quire two injections a day.
In contrast to recent data reported by Neggers et al.
[28], we—like VanderLely et al. [11]—found no significant
differences between the PEGV and PEGV+ SSA treatment
Figure 2 (See legend on next page.)
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Figure 2 Relationship between duration of PEGV therapy and final daily dose according to outcome. Correlation between duration of
PEGV therapy (months) and final daily PEGV dose (mg/day) in all patients (both groups) with IGF-I normalization at the end of follow-up (A, upper
panel, ◊) and all patients (both groups) with non-normalized IGF-I levels at the end of follow-up (B, lower panel, Δ). Regression coefficient (r) and
p value are shown.
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patients controlled. At the time of diagnosis, Group 2 pa-
tients had more marked biochemical derangements than
those of Group 1, but when SSA monotherapy was
discontinued, the GH and IGF-I levels of the two groups
were similar. However, the same dose of PEGV appears to
have been more effective when administered alone than it
was when administered with an SSA. In all probability,
this was due mainly to the fact that patients who received
PEGV + SSA had more aggressive disease.
Treatment duration was significantly longer in patients
being managed with PEGV monotherapy. Many of these
were among the first in Italy to be treated with PEGV, and
they may well have been selected precisely because their
disease was relatively mild, with small tumors / residual
tumors and IGF-I and GH levels considered more likely to
be controlled safely by the new drug (based on data avail-
able at that time). It is important to recall that we did not
analyze the reasons for the two groups’ different responses
to SSA monotherapy. Multiple biochemical and clinical
factors are known to influence the response to these drugs
[21], and an analysis of this type was beyond the scope of
our study. In contrast with the findings of Trainer et al.
[29], the final PEGV doses being used by patients who
were not controlled (in either group) were no lower than
those of the patients with normal IGF-I levels at the end
of follow-up. Within Group 2, PEGV doses for the uncon-
trolled subset of patients were higher than those being
used by the normalized subset, which suggests that at-
tempts had been made (albeit unsuccessfully) to achieve
control by dose increases. Previous short-term [30,31] and
long-term [32] studies have demonstrated that the PEGV
dose required for IGF-I normalization is influenced by
various factors, including body weight, sex, previous radio-
therapy, baseline GH and IGF-I levels, and GH-receptor
(GHR) polymorphisms, although a more recent study
failed to confirm the importance of the last factor in re-
sponses to PEGV or to PEGV + SSA [24]. According to
other authors [24], our data showed that both monother-
apy or combination and final dose of PEGV are not af-
fected by previous radiotherapy, probably because that
was performed only in about 26% of patients, whereas the
same treatment was reported in a high proportion of pa-
tients (58-66%) in previous studies [30,32]. Our findings
are the first that reveal a strong linear relation between
the IGF-I-normalizing dose and the duration of PEGV
treatment, regardless of whether the latter is combined
with SSAs. This correlation was not significant in patientswho failed to achieve IGF-I normalization at the end of
follow-up, probably because these patients had more ag-
gressive disease with higher levels of GH. Inadequate dose
adjustment may also have played a role.
Previous studies [8,9,11] indicate that the percentage of
patients controlled by PEGV remains stable over time. The
earliest studies, which were short-term trials, showed that
higher doses were associated with proportionally higher
control rates, and that the dose required to achieve
normalization depended on pre-PEGV IGF-I levels [14,23].
In healthy subjects, PEGV, a selective competitive
GHR antagonist [33], decreases plasma IGF-I levels and
increases blood GH concentrations [34]. Despite in vitro
and in vivo studies have demonstrated a direct action of
pegvisomant on different organs and tissues [35] and a
possibile direct role in chemoresistance [36,37], data
concerning direct effects of PEGV on GH secretion by
pituitary adenoma are conflicting. Some studies have ob-
served an impairment of GH autofeedback in
somatotrophs [38,39], whereas other investigators have
demonstrated that PEGV does not effect pituitary
somatotrophs directly and it does not cross the human
blood–brain barrier [40,41], thus favoring GH-secretion
indirectly via IGF-I lowering.
In our study, the PEGV dose probably has to be progres-
sively increased over time to maintain IGF-I levels within
target ranges, particularly in the documented presence of
residual GH-secreting tumor tissue. An “escape”
phenomenon of this type has been reported by several
groups [32,42,43]. Although still poorly defined, it has been
linked to diverse factors, including distracted physicians,
noncompliant patients, and intrinsic features of the aden-
oma itself [44]. In our opinion, it may also stem from the
increasing GH hypersecretion documented during PEGV
therapy [8,19]. In patients who are SSA-resistant and there-
fore have persistently high levels of GH and IGF-I pro-
duced by an aggressive type of adenoma, it is conceivable
that the dose of PEGV (regardless of whether it is given
alone or with an SSA) will have to be periodically increased
over time to control rising GH production. This hypothesis
naturally needs to be confirmed with additional studies in
larger populations, but physicians should be aware that on-
going monitoring of treatment responses is essential, even
after IGF-I normalization has been achieved.
Conclusions
We found for the first time that, in SSA-refractory GH-
pituitary tumours, combination therapy (PEGV + SSA)
Bianchi et al. Journal of Experimental & Clinical Cancer Research 2013, 32:40 Page 10 of 11
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ical/biochemical/imaging evidence of relatively severe/
aggressive disease along with a more substantial (albeit
incomplete) IGF-I response to SSA monotherapy (PEGV
alone). Both regimens were well tolerated, and at the
end of follow-up, there was no significant difference be-
tween the daily PEGV doses in the two groups. However,
our data show that, in SSA-resistant acromegaly, the final
PEGV dose increases with treatment duration and there-
fore, for all patients, special attention is required, as there
is a need for continuous PEGV dose-adjustement during
long-term follow-up.
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